SCHEMBL18166537

SCHEMBL18166537

CCOC(=O)c1ccc2nc(NC(=O)Cn3cnc4c3c(=O)n(C)c(=O)n4C)sc2c1

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.78
▸ KDM4E B2RXH2 2/20 0.78
▸ ATM Q13315 1/20 0.78
▸ GAA P10253 1/20 0.67
▸ RXFP1 Q9HBX9 5/20 0.58
▸ NPC1 O15118 3/20 0.58
▸ RAB9A P51151 3/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ TP53 P04637 2/20 0.56
▸ STAT1 P42224 1/20 0.55
▸ MAPT P10636 1/20 0.53
▸ USP2 O75604 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ CYP1A2 P05177 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18166543 0.87 KDM4E (1.00) TSHRKDM4EATMRXFP1NPC1
SCHEMBL10113950 0.87 KDM4E (0.78) TSHRKDM4EATMRXFP1SMN1; SMN2
SCHEMBL10113944 0.85 KDM4E (0.85) TSHRKDM4EATMRXFP1TP53
SCHEMBL18166760 0.85 KDM4E (0.77) TSHRKDM4EATMRXFP1SMN1; SMN2
SCHEMBL18166564 0.85 KDM4E (0.77) TSHRKDM4EATMRXFP1SMN1; SMN2
SCHEMBL18166769 0.83 KDM4E (0.72) TSHRKDM4EATMRXFP1SMN1; SMN2
SCHEMBL18166652 0.83 RXFP1 (0.65) TSHRKDM4EATMGAARXFP1
SCHEMBL10114083 0.83 KDM4E (0.73) TSHRKDM4EATMRXFP1SMN1; SMN2
SCHEMBL10113978 0.82 KDM4E (0.73) TSHRKDM4EATMRXFP1SMN1; SMN2
SCHEMBL18166688 0.82 KDM4E (0.73) TSHRKDM4EATMRXFP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3663295-A1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL ELI LILLY AND CO. (US) 2020-06-10 — — EP disclosed
EP-3184527-A1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL Hydra Biosciences, Inc. (US) 2017-06-28 — — EP disclosed
EP-2170309-B1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL HYDRA BIOSCIENCES INC (US) 2016-10-26 — — EP disclosed
Send feedback